MDC Max Delbrück Center for Molecular Medicine in the Helmholtz Association
The MDC Max Delbrück Center for Molecular Medicine in the Helmholtz Association ranks among the top institutions in the world for basic biomedical research. MDC scientists use state-of-the-art methods of molecular biology and genetic engineering in order to understand the development of complex diseases at their origin, in the genes. On this basis, they seek to develop new methods to diagnose, treat and prevent diseases. Research activities at the MDC are divided into four main areas: cardiovascular and metabolic diseases, cancer, diseases of the nervous system and medical systems biology. MDC researchers collaborate closely with the Charité in the Experimental and Clinical Research Center and also with biotech companies located on Campus Berlin-Buch. The MDC currently employs approximately 1,700 staff members, including guest scientists, and has state-of-the-art technology platforms such as 7 Tesla ultra high field MRI, electron microscopy or bioinformatics.
Leibniz Research Institute for Molecular Pharmacology (FMP)
How do diseases develop? Which drugs can specifically target and intervene in the biochemistry of the body? Research activities at the Leibniz Research Institute for Molecular Pharmacology (FMP), Germany’s only non-university research institute for pharmacology, are concerned with these questions. Chemists, biologists, pharmacologists, physicists and physicians collaborate closely to lay the basis for the development of future drugs.
The FMP cooperates with other Berlin research institutions such as the Max Delbrück Center for Molecular Medicine and Charité-Universitätsmedizin Berlin and is part of several research projects, such as the Neurocure cluster of excellence. The institute is also one of the initiators of the large-scale European project EU-OPENSCREEN, in which institutions from various European countries want to coordinate the search for new drugs, and part of the new European network “Instruct”, which seeks to link the highly sophisticated technologies in structural biology.
The institute has a staff of 300 employees and is a member of the Leibniz Association and the Forschungsverbund Berlin e.V. (Berlin Research Association).
Inhibitor of lipid kinase PI3KC2α identified as potential new treatment of thrombosis
The lipid kinase PI3KC2α is a potential pharmacological target for the treatment of thrombosis and, possibly, cancer. Researchers from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP)...more ...
Dense and permeable: molecular organization of tight junctions decoded
They seal epithelial cells and, under certain conditions, allow the passage of ions and water: Tight junctions form a paracellular barrier in tissues and their dysfunction is associated with diseases ...more ...
Million euro support for MyoPax
MyoPax, a new spin-off of the Max Delbrück Center and Charité, receives a 1.3 million euros loan to jump-start its entrepreneurial activities. The start-up develops regenerative therapies for previous...more ...
Auf der Suche nach der Gesundheit - Wie Forschung funktioniert
Vorlesungsreihe: Neue Wege in der Biomedizin: Aktuelle Forschungsthemen vom Campus Berlin-Buchmore ...
Bioinformatik im Labor 4.0
Eine eintägige Einführung für Technische Angestellte und Laborant*innen in die aktuelle Bioinformatik und in das Next Generation Sequencing (NGS) mit praktischen Übungen zum Umgang mit Biodatenbanken.more ...
CampusVital LOUNGE: Ersthelfer-Kurse für psychische Gesundheit
Am 10. Oktober ist der Internationale Tag der seelischen Gesundheit. Wir greifen dieses wichtige und hoch aktuelle Thema auf und stellen die MHFA Ersthelfer-Ausbildung vormore ...